The high rates of protein synthesis and processing render multiple myeloma (MM) cells vulnerable to perturbations in protein homeostasis. The induction of proteotoxic stress by targeting protein degradation with proteasome inhibitors (PIs) has revolutionized the treatment of MM. However, resistance to PIs is inevitable and represents an ongoing clinical challenge. Our first-in-human study of the selective inhibitor of RNA polymerase I transcription of ribosomal RNA genes, CX-5461, has demonstrated a potential signal for anti-tumor activity in three of six heavily pre-treated MM patients. Here, we show that CX-5461 has potent anti-myeloma activity in PI-resistant MM preclinical models
Kylee Maclachlan, Kezia Gitareja, Jian Jian Kang, Andrew Cuddihy, Yuxi Cao, Nadine Hein, Carleen Cullinane, Ching‐Seng Ang, Natalie Brajanovski, Richard B. Pearson, Amit Khot, Elaine Sanij, Ross D. Hannan, Gretchen Poortinga, Simon J. Harrison
Richard J. Rebello, Eric Kusnadi, Donald P. Cameron, Helen Pearson, Analia Lesmana, Jennifer R. Devlin, Denis Drygin, Ashlee K. Clark, Laura H. Porter, John Pedersen, Shahneen Sandhu, Gail P. Risbridger, Richard B. Pearson, Ross D. Hannan, Luc Furic
Richard J. Rebello, Eric Kusnadi, Don P. Cameron, Helen Pearson, Analia Lesmana, Jennifer R. Devlin, Denis Drygin, Ashlee K. Clark, Laura H. Porter, John Pedersen, Shahneen Sandhu, Gail P. Risbridger, Richard B. Pearson, Ross D. Hannan, Luc Furic
Denis Drygin, Amy Lin, Josh Bliesath, Caroline B. Ho, Sean O’Brien, Chris Proffitt, Mayuko Omori, Mustapha Haddach, Michael K. Schwaebe, Adam Siddiqui-Jain, Nicole Streiner, Jaclyn Quin, Elaine Sanij, Megan J. Bywater, Ross D. Hannan, David M. Ryckman, Kenna Anderes, William G. Rice
Richard J. Rebello, Eric Kusnadi, Donald P. Cameron, Helen Pearson, Analia Lesmana, Jennifer R. Devlin, Denis Drygin, Ashlee K. Clark, Laura S. Porter, J.K. Pedersen, Shahneen Sandhu, Gail P. Risbridger, Richard B. Pearson, Ross D. Hannan, Luc Furic
Discussion(0)
No comments yet. Be the first to comment.